CEO: Phillip Gomez, Ph.D
HQ: New York, NY
SIGA is a leader in the development and commercialization of solutions that address the critical need for therapies that treat bioterrorism agents. TPOXX® (tecovirimat), the company’s lead investigational product, is designed to treat smallpox, a deadly bioterrorism threat that cannot be addressed through vaccines alone. While the U.S. Food & Drug Administration has not yet approved TPOXX as safe or effective, SIGA has received a $472 million procurement and development contract with the U.S. government to provide two million courses of oral TPOXX to the Strategic National Stockpile under congressionally-authorized Project BioShield. Approval of TPOXX may entitle SIGA to a Priority Review Voucher, a valuable asset that may be sold on the open market. The company also has a development contract from the U.S. Government for an intravenous formulation of TPOXX as well as a preclinical program supported by NIH focused on developing an antiviral agent to treat dengue virus. SIGA’s experienced management team and strategic collaborations enhance the company’s prospects for success in the estimated $9.5 billion global biodefense market.